Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
November 8, 2022 4:01 PM ESTUDENYCA® net sales of $45.4 million in the third quarter 2022 CIMERLI launched in the United States on October 3rd Planning underway for 2023 commercial launches of toripalimab, YUSIMRY and UDENYCA® OBI Conference call today at 5 p.m. ET
REDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for its fiscal third quarter ended September 30, 2022 and recent business highlights:
RECENT BUSINESS HIGHLIGHTS
CIMERLI (ranibizumab-eqrn), was approved in August 2022 by... More